Urokinase-type plasminogen activator (uPA) binds to its receptor (uPAR) with a K d of about 1 nM. The catalytic activity of the complex is apparent at uPA concentrations close to K d . Other functions of the complex, such as signal transduction, are apparent at much higher concentrations (35-60 nM). In the present study, we show that uPA and recombinant soluble uPAR (suPAR), at concentrations that exceed the K d and the theoretical saturation levels (10 -80 nM), establish novel interactions that lead to a further increase in the activity of the single-chain uPA (scuPA)/suPAR and two-chain uPA (tcuPA)/suPAR complexes. Experiments performed using dynamic light scattering, gel filtration, and electron microscopy techniques indicate that suPAR forms dimers and oligomers. The three techniques provide evidence that the addition of an equimolar concentration of scuPA leads to the dissociation of these dimers and oligomers. Biacore data show that suPAR dimers and oligomers bind scuPA with decreased affinity when compared with monomers. We postulate that uPAR is present in equilibrium between oligomer/dimer/monomer forms. The binding of uPA to suPAR dimers and oligomers occurs with lower affinity than the binding to monomer. These novel interactions regulate the activity of the resultant complexes and may be involved in uPA/ uPAR mediated signal transduction.
in wild-type mice also correlates with fibrin deposition in response to endotoxin (5) . Additional biologic functions that have been attributed to uPA and its receptor include cell adhesion (6 -17) and differentiation (18 -24) .
uPA binds to its receptor (uPAR) with a K d of about 1 nM (25, 26) , forming a stable complex with an off-rate of several hours. The resultant complex has been shown to be involved in two separate biological cascades: (a) plasminogen activation, which results in proteolytic activity, and (b) signal transduction, which results in cell adhesion and mitogenesis. Plasminogen activation by the complex between uPA and its receptor is apparent at concentrations close to the determined K d (27) (28) (29) , whereas signal transduction is apparent only at much higher concentrations (35-65 nM) (30, 31) . The lack of agreement between the concentrations required for signal transduction and the K d has led to the assumption that the uPA receptor is not involved in uPA-induced signal transduction (30) .
An alternative explanation for the lack of agreement between the known K d and the uPA concentration needed to induce signal transduction is the existence of additional binding epitopes in both uPA and uPAR, which interact with lower affinity. The possible presence of more than one kind of interaction is supported by our data (32) and the data of others (33) , which indicate that uPAR contains several binding epitopes that participate in the binding of uPA to uPAR.
In the present paper we demonstrate the existence of such low affinity interactions. These novel interactions correlate with a modification of the activity of the resultant scuPA/ suPAR complex and further activation of tcuPA by suPAR. Furthermore, the low affinity interaction stems from the capacity of suPAR to form dimers and oligomers that bind scuPA with relatively lower affinity and dissociate by the addition of an equimolar concentration scuPA.
EXPERIMENTAL PROCEDURES

Materials
scuPA, the amino-terminal fragment of scuPA (amino acids 1-135; ATF), low molecular weight scuPA (amino acids 145-411; LMWscuPA), and low molecular weight tcuPA, scuPA, and suPAR (in part) were all gifts of Dr. Jack Henkin (Abbott Laboratories, Abbott Park, IL) and were characterized as described in previous publications (32, 34) . Neutralizing polyclonal anti-uPAR antibodies were a gift of Dr. Douglas Cines from the University of Pennsylvania. Human thrombin was obtained from Sigma. tcuPA, Glu-plasminogen, and the plasmin substrate Spectrozyme PL were purchased from American Diagnostica (Greenwich, CT). Plasma was obtained from the Hadassah Hospital Blood Bank (Jerusalem). Blood used to obtain plasma was drawn from healthy volunteers. 450 ml of blood were collected in bags produced by Travenol Laboratories (Ashdod, Israel), containing 63 ml of citratephosphate-dextrose (CPD) solution (1.66 g of sodium citrate (hydrous), 61 g of dextrose, 206 mg of citric acid, and 140 mg of monobasic sodium * This work was supported in part by Grants HL60169 (to A. A. H.), HL58107 (to A. A. H.), and HL30954 (to J. W. W.) from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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§ § To whom correspondence should be addressed: Dept. of Pathology and Laboratory Medicine, 513A Stellar-Chance, 422 Curie Blvd., Philadelphia, PA 19104. Fax: 215-573-2012; E-mail: abd@md2.huji.ac.il. 1 The abbreviations used are: uPA, urokinase-type plasminogen activator; uPAR, uPA receptor; scuPA, single-chain uPA; tcuPA, two-chain uPA; ATF, amino-terminal fragment of urokinase; LMW, low molecular weight; suPAR, recombinant soluble uPA; MES, 4-morpholineethanesulfonic acid; HPLC, high pressure liquid chromatography; EM, electron microscopy; PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; SEC, size exclusion chromatography. phosphate). Plasma was separated by centrifugation at 2500 rpm for 7.5 min and at 4500 rpm for an additional 5 min to remove platelets.
Methods
Production of suPAR-cDNA encoding soluble uPAR (amino acids 1-277), was generated by polymerase chain reaction using pTraceruPAR as templates. The fragments were digested with BglII and Xho and sub-cloned into the expression vector (pMT/BiP/V5, Invitrogen). Wild-type suPARs was expressed in Drosophila Schneider S2 cells (DES system, Invitrogen) as described by the manufacturer and purified from the media using a polyclonal anti-uPAR antibody affinity column. SuPAR from Abbott Laboratories (see "Materials") was in use too.
Measurement of Plasminogen Activator Activity-The plasminogen activator activity was measured in the presence of plasminogen and the plasmin substrate Spectrozyme PL (28) . Increasing concentrations of scuPA in the absence or presence of 5 nM suPAR were incubated with 20 nM Glu-plasminogen and 0.5 mM Spectroyme PL in phosphate-buffered saline (PBS), pH 7.4, for 20 min. The reaction was monitored at 405 nm. In another set of experiments, 5 nM scuPA was incubated in the absence or presence of different concentrations of suPAR. In control experiments, a 10-fold molar excess of ATF or 100 nM anti-suPAR antibodies were added to suPAR before its addition to the reaction mixture.
Kinetic analysis of the plasminogen activation was performed as described ( (28, 35) . Briefly, an equimolar concentration of the scuPA/ suPAR complex (5 nM) was incubated in the presence or absence of an additional 5 nM suPAR and increasing concentrations of Glu-plasminogen and Spectrozyme PL in PBS, pH 7.4, at 37°C. The concentration of generated plasmin was calculated during each time interval from the rate of change at 405 nm using a standard curve made with known concentrations of plasmin. The kinetic parameters of plasmin generation were then plotted using a double-reciprocal plot of the rates of plasmin generation versus plasminogen concentration.
Fibrinolysis Assessed by Release of Radioactivity-Purified fibrinogen was radiolabeled with 125 I and resuspended in plasma to a specific activity of 30,000 cpm/ml. Clots were formed in 16-mm diameter tissue culture wells (Costar, Cambridge, MA) by adding 0.4 NIH units to 0.4 ml of plasma. Fibrinolysis was measured as described previously (41) . Briefly, radiolabeled fibrin clots enriched with 100 nM plasminogen were overlaid for 1 h at 37°C with 0.4 ml of serum containing 25 nM plasminogen activator (scuPA or tcuPA, in the absence or presence of increasing concentrations of suPAR), and the release of radiolabeled soluble fibrin degradation products was measured.
Size Exclusion Chromatography (SEC)-A TSK3000SW SEC column (Beckman) was equilibrated with PBS. Samples (0.1 ml total volume) were injected using a 0.2-ml loop, and the column was developed with PBS at a flow rate of 1 ml/min. Absorbance was measured at 220 nm, and data were collected using a Beckman Gold Chromatography system.
Dynamic Light Scattering-Dynamic light scattering was performed with a Dynapro-801 molecular sizing instrument (Protein Solutions, Inc., Charlottesville, VA) equipped with a 20-l micro-sampling cell at room temperature (22°C). suPAR and scuPA were in a buffer of 20 mM Tris, pH 7, and 10 mM MES, pH 5.0, respectively, and were concentrated to 2 mg/ml. A complex of suPAR and scuPA was made at 1:1 ratio. All protein solutions were filtered through a membrane of 0.02 l porosity to remove any dust prior adding to the micro-sampling cell. Fifteen to 20 l of solutions was used to measure the light-scattering signal. For each sample, at least 10 light-scattering measurements were taken, and the data were processed by Protein Solution's DynaLS and DYNAMICS software, version 4.0.
Electron Microscopy of uPA and suPAR-Rotary-shadowed samples were prepared by spraying a dilute solution of protein (final concentration about 15 g/ml) in a volatile buffer (0.05 M ammonium formate, pH 7.4) and 70% glycerol onto freshly cleaved mica and shadowing with tungsten followed by deposition of a carbon film in a vacuum evaporator (Denton Vacuum Co., Cherry Hill, NJ) (36 -38) . Preparations of scuPA, suPAR, and mixtures of the suPAR/scuPA were made at a molar ratio of 2.5:1. The specimens were examined in a Philips 400 electron microscope (FEI Co., Hillsboro, OR) operating at 80 kV. All experiments were repeated several times, and many micrographs were taken of randomly selected areas to ensure that the results were reproducible and representative. About 1000 particles were counted to determine the prevalence of different particles.
Surface Plasmon Resonance-Binding of scuPA to suPAR was measured using a BIA 3000 optical Biosensor (Biacore, AB, Sweden) (39) . This method detects binding interactions in real time by measuring changes in the refractive index at a biospecific surface and enables association and dissociation rate constants to be calculated. For these studies, recombinant suPAR and recombinant scuPA were coupled to CM5 research grade sensor chip flow cells (Biacore) via standard amine coupling procedures (40) using N-hydroxysuccinimide/methyl-NЈ- [3-(dimethylamino) propyl] carbodiimine hydrochloride (Pierce) at a level of 1000 relative units each. Sensor surfaces were coated with ligands (10 g/ml) in 10 mM NaAc buffer, pH 5.0. Following immobilization, unreacted groups were blocked with 1 M ethanolamine, pH 8.5. A third flow cell, similarly activated and blocked without immobilization of protein, served as a control surface. The binding buffer was PBS, pH 7.4, 0.005% Tween 20. Binding of scuPA was measured at 25°C at a flow rate of 30 l/min for 6.7 min followed by 3 min of dissociation. The bulk shift due to changes in the refractive index was measured using the control surface and was subtracted from the binding signal at each condition to correct for nonspecific signals. Surfaces were regenerated with a single 30-s pulse of 1 M NaCl, pH 3.4, followed by an injection of binding buffer for 1 min to remove this high salt solution. All injections were performed in a random fashion using the RANDOM command in the automated method. The response at equilibruim (Req) was calculated as the average response over the last 10 s of association.
Data were analyzed by both linear (Scatchard) and nonlinear regression. Linear transformation (43) was performed using Excel 97 software, fitting the equation
where R eq is the response at equilibrium, C is the concentration of analyte in solution, K d is the equilibrium dissociation constant, and R max is the maximal specific binding to the surface. Nonlinear regression was performed using GraphPad PRISM 2.0 fitting the binding isotherm directly (R eq ϭ C⅐R max /(C ϩ K d ).
RESULTS
Our previous data, as well as those of other laboratories, show that suPAR stimulates the activity of scuPA at concentrations equal or close to the K d (27) (28) (29) . In the initial experiments, we examined the effect of increasing the concentrations of the ligands on the activity of the resultant complex. ScuPA (5 nM) was incubated with increasing concentrations of suPAR. As expected, the addition of an equimolar concentration of su-PAR stimulated the plasminogen activation activity of scuPA ( Fig. 1 ). An additional increase in the concentration of suPAR resulted in a further increase in scuPA activity. The stimulatory effect of suPAR was dose-dependent and saturable. SuPAR alone had no plasminogen activation activity. The presentation of the data as a reciprocal plot (Fig. 1B) shows that halfmaximal stimulation was achieved at a suPAR concentration of 30 nM.
To prove that the apparent saturation resulted from a limited scuPA/suPAR interaction and was not the result of other limiting factors, such as the amount of plasminogen, or of the chromogenic plasmin substrate, we added additional amounts of scuPA in the plateau region of the curve (scuPA/suPAR ratio 5/80). Fig. 2 shows that by increasing the concentration of scuPA from 5 to 10 nM at a fixed concentration of suPAR (80 nM, which gave a maximal response at 5 nM suPAR), a further increase of scuPA activity was obtained. In addition, Fig. 2 shows that the stimulatory effect of suPAR on scuPA activity could be abolished by the addition of ATF. This observation supports the conclusion that the observed plateau was the result of a limited interaction with suPAR. The inhibitory effect of ATF indicates that the additional interactions depend on the occurrence of primary binding between scuPA and suPAR through the ATF. To further support the role of suPAR in the stimulatory effect, we added polyclonal anti-uPAR antibodies. Fig. 2 shows that the anti-uPAR antibodies had the same inhibitory effect as ATF, whereas irrelevant IgG has no effect on the activity of the complex (not shown). Fig. 3 shows that at a scuPA/suPAR ratio of 1:2, the V max , but not the K m , was greater than with equimolar concentrations. The increase in the V max could also be the result of contamination of suPAR by uPA, but this possibility could be excluded because suPAR alone had no activity (Fig. 1) and ATF inhibited the activity. Another possibility is the presence in suPAR of a protease that cleaves scuPA to tcuPA. To exclude this possibility, we incubated scuPA with suPAR for 24 h. Under these conditions, scuPA continued to migrate as a single band when analyzed by reducing SDS-PAGE as described elsewhere (28) (data not shown).
These results suggest that suPAR establishes novel interactions with scuPA that are apparent only at higher concentrations of the ligands and that participation of these binding epitopes induces additional conformational changes in the complex, leading to further activation. To support these conclusions, we used a clot lysis assay. Fig. 4A shows that the scuPAmediated fibrinolysis of human plasma-derived clots was stimulated in a dose-dependent and saturable manner by su-PAR concentrations that exceeded those of scuPA and the K d .
In previous publications, we showed that suPAR had almost no effect on tcuPA activity when both ligands were present in equimolar concentrations (28, 41) . The next question to be addressed was, therefore, whether interactions established at higher concentrations of suPAR affected tcuPA activity. Fig. 4B shows that tcuPA-mediated fibrinolytic activity on human plasma clots was stimulated by suPAR. Marginal stimulation (10%) was observed at a 1:1 concentration ratio, and a further increase of suPAR concentration induced a dose-dependent and saturable stimulation. Maximal stimulation (more than 5-fold) was obtained at tcuPA/suPAR ratios of 1:6. To exclude the possibility that the stimulation was the result of suPAR activity on contaminating scuPA, tcuPA was analyzed by SDS-PAGE. Overloaded gels did not reveal the presence of scuPA in the preparation (not shown).
To determine whether the effect of suPAR was due to binding to tcuPA or to some other mechanism, we examined the effect of ATF on the stimulation by suPAR. Fig. 4B shows that the effect of suPAR on tcuPA could be completely inhibited by ATF and that suPAR had no effect on the activity of LMWuPA. Anti uPAR antibodies abolished the effect of suPAR on tcuPA (not shown). In addition, ATF inhibited the stimulatory effect of suPAR on scuPA-mediated fibrinolysis, and suPAR had no effect on LMWscuPA activity (Fig. 4A) .
It is widely accepted that uPA binds to suPAR at a 1:1 ratio. uPA binds to its receptor with high affinity and a K d of 1 nM. The observation that suPAR exerts a stimulatory effect at concentrations that exceed the 1:1 ratio and the theoretical saturating concentrations suggests the existence of another kind of interaction of suPAR with uPA. This additional interaction proceeds with relatively lower affinity and leads to additional functional modification of the uPA/uPAR complex. This hypothesis is supported by the observation that the activity of the resultant complex is higher and by data from the literature that demonstrate that uPA-induced signal transduction is observed only at concentrations that are much higher than would be predicted from the K d of the bimolecular complex formation (30, 42) .
In an attempt to verify the existence of previously unknown interactions between uPA and uPAR, we used several different approaches. First, we used the size exclusion technique. Fig. 5A shows that suPAR exhibited a complex equilibrium when analyzed by SEC-HPLC. SuPAR migrated in two peaks at 4.7 and 8.1 min retention time (RT). In contrast, scuPA migrated as a single peak of 10.9 RT (not shown). Fig. 5B shows that on SDS-PAGE, scuPA and suPAR injected into the HPLC run as single bands.
In an attempt to examine the effect of scuPA on the equilibrium between the different forms of suPAR, we incubated scuPA with suPAR at several molar ratios. Fig. 5B shows the results of the addition of scuPA at a 1:2 ratio (suPAR excess). Under these conditions, no monomeric scuPA was present, and the second suPAR peak migrated at 8.4 rather than 8.1 min. SDS-PAGE analysis of the protein present in this peak demonstrated that it represents a scuPA-suPAR complex (Fig. 6B) . Fig. 5C presents the results of the addition of scuPA at a 1:1 ratio. Under these conditions, scuPA shifted both peaks of suPAR to a peak of RT ϭ 8.4 min, which represents the scuPA/ suPAR complex (Fig. 6B) . These data suggest that the higher molecular mass form of suPAR is able to interact with scuPA, albeit at a lower affinity.
It should be noted that the monomeric scuPA-suPAR complex elutes with a RT (8.4 min) comparable with the 8.1-min peak of suPAR. This fact suggest that the suPAR that eluted with RT ϭ 8.1 min is a dimer.
The size exclusion technique shows the status of the isolated ligands and complexes but does not provide information as to the situation under equilibrium conditions. To examine the status of the reactants under equilibrium conditions, we used dynamic light scattering. The dynamic light scattering measures translational diffusion coefficients (D T ) of proteins through monitoring the scattered light of protein in solution. Based on D T, the hydrodynamic radius (R h ) of the protein can be calculated using the Stokes-Einstein equation: R h ϭ k b T/ 6D T, with Boltzmann's constant (k b ), solvent viscosity (), and temperature Kelvin (T). The molecular weight of the protein is then estimated by fitting the measured R h to a standard curve derived from 25 globular proteins. Proteins that are either nonspherical in shape or partially unfolded will show apparent molecular weights that are higher than their theoretical molecule weights. Fig. 7A shows the regularization histogram of scuPA, and illustrates that scuPA is primarily a single species in aqueous solution. Using a monomodal cumulatant analysis, scuPA was found to have an averaged hydrodynamic radius (R h ) of 3.77 nm with 16% polydispersity (0.6 nm), corresponding to an apparent molecular mass of 73 kDa, based on the standard size/weight relationship for globular proteins.
The matrix-assisted laser desorption ionization (MALDI) mass spectrum of scuPA and SDS-PAGE of scuPA gave a molecular mass of 48,140 Da and ϳ47 kDa, respectively (data not shown), and both are close to its theoretical molecular mass, 46,511 Da, derived from protein sequence. The difference of apparent molecular weight from mass when compared with theoretical calculation is believed to be due to the contribution of the carbohydrate present in the protein.
In contrast to the monodispersity of scuPA, the regularization histogram of suPAR (Fig. 7B ) reveals some large aggregates with an R h ϳ40 nm along with small size aggregates (R h ϳ4 nm). Monomodal cumulatant analysis gives an R h of 5.32 nm and a 45% polydispersity (2.4 nm), corresponding to a molecular mass of 167 kDa. This large polydispersity also clearly suggests the existence of aggregates. A bimodal cumulatant analysis, assuming the existence of two species of suPAR in the aqueous solution, suggests that 98% of suPAR has an R h of 4.2 nm, corresponding to an apparent molecular mass of 97.7 kDa, and the remaining 2% has an R h of 19.3 nm, corresponding to an apparent molecular mass of 5109 kDa.
Upon combination of suPAR with scuPA at a 1:1 ratio, the light-scattering pattern appears to be monodispersed with an R h of ϳ4.1 nm and 19% polydispersity, corresponding to a molecular mass of 91 kDa (Fig. 7C) . The lack of a signal at R h ϭ 3.77 demonstrates the absence of uncomplexed scuPA. These data are consistent with the dissociation of suPAR dimers for the preferential formation of 1:1 scuPA:suPAR complexes.
The scuPA/suPAR complex is smaller in size (4.1 nm) than the suPAR dimer (4.2 nm). This finding is in agreement with the SEC data showing that the scuPA/suPAR complex elutes with a longer RT as compared with suPAR dimers (RT ϭ 8.4 versus 8.1 min). The combined data of SEC and dynamic light scattering suggest a more compact and smaller hydrodynamic radius in the scuPA-suPAR complex.
We also used electron microscopy to determine the nature of the complexes formed between scuPA and suPAR. Rotary shadowed preparations of suPAR were examined by electron microscopy. The protein was initially at a concentration of 20 M and was diluted about 200ϫ into 0.05 M ammonium formate at pH 7.4 and 70% glycerol just before spraying onto mica, prior to further preparation for microscopy. Electron microscopic examination revealed two different particles (Fig. 8A) . The smaller of the two was a globular particle with a diameter of about 10 nm or about 7-8 nm after subtraction of the thickness of the coating of metal. The larger particle consisted of two of the smaller nodules side-by-side to form dimers. Under the buffer and protein concentration conditions of this experiment, 41% of the particles or 55% of the protein were in the form of dimers and 2% of the particles or 5% of the protein were trimers, whereas the remainder were monomers. It should be noted, however, that these numbers cannot be compared directly with the SEC or light-scattering results because of the different buffer and protein concentrations.
Rotary-shadowed preparations of scuPA were also examined by electron microscopy (Fig. 8B) . These molecules appeared to be globular particles just slightly larger in size than the suPAR 1 mg) ; B, the addition of scuPA in a 2:1 suPAR:scuPA ratio (suPAR excess); C, the addition of scuPA in a 1:1 ratio (equal scuPA and suPAR).
particles, but they were entirely monomeric. The difference in size is consistent with the difference in molecular mass; scuPA has 411 amino acids, whereas suPAR has 282 amino acid residues. Some particles appeared to be oblong with an axial ratio of about 0.85, while others were nearly the same in both dimensions. These two types of images may represent different views of the same structure.
Electron microscopy (EM) was also carried out on rotaryshadowed preparations of scuPA and suPAR incubated together for 30 min. In images of a mixture of suPAR and scuPA, there were also monomeric and dimeric structures. The small difference in size of scuPA and suPAR did not allow us to unequivocally identify monomers as one or the other in these mixtures (Fig. 8C) .
Optical biosensors were employed to further examine the data obtained by size exclusion, which suggested that some forms of suPAR bind scuPA less efficiently than others. The data obtained by size exclusion, dynamic light scattering, and EM show that suPAR, but not scuPA, dimerizes/aggregates. Our aim, therefore, was to compare the behavior of both molecules in solution and to see how the postulated dimerization/ aggregation of suPAR affects its affinity toward scuPA. For this purpose, either suPAR or scuPA were immobilized to CM5 carboxymethydextran biosensor surfaces, and the corresponding ligand was added at various concentrations. A wide range of concentrations was used to examine concentrations that induce scuPA activity (Figs. 1 and 4A ) as well as signal transduction. To avoid relying on kinetic data (which are more likely to be affected by immobilization chemistry), analysis of equilibrium binding was performed to determine ligand affinity. Nonlinear regression of the single-site bimolecular binding isotherms was performed for both the binding of scuPA to suPAR (Fig. 9, A and C) and suPAR to scuPA (Fig. 9, B and  D) . For scuPA in solution, a K d of 4.2 Ϯ 0.6 nM was obtained (R 2 ϭ 0.98) whereas a K d of 65 Ϯ 8 nM (R 2 ϭ 0.99) was calculated when suPAR was in solution. As seen by the values of R 2 , the fit for this model was quite good. Interestingly, for linear regression of Scatchard-transformed data, this was not the case, specifically when suPAR was in solution. As can be seen from the plots, the data for suPAR in solution is curvilinear, suggesting a more complex binding interaction, whereas a linear plot is obtained with scuPA in solution. One known cause of such deviation from linearity is dimerization of ligand in solution, which lowers the effective concentration of monomer (43); this not only results in a curvilinear Scatchard plot, but also in an apparent increase in K d . These data give further support to the formation of suPAR dimmers in solution. Furthermore, these data demonstrate directly that this dimerization decreases the effective affinity of scuPA for its receptor. DISCUSSION Our data show that scuPA and suPAR are able to establish a novel interaction that appears at concentrations that are higher than the accepted K d and the predicted saturation. These interactions result in increased activity of the complex with half-maximal activity at 30 nM. These conclusions are based on several observations, which follow.
The increase of suPAR concentrations to levels that exceed the theoretical saturation of a simple 1:1 complex induces a further stimulation of scuPA/suPAR activity. The stimulatory effect of suPAR cannot be attributed to contaminants or artifacts for several reasons. 1) Because suPAR by itself has no plasminogen activation activity, contamination by PA cannot be a factor. 2) scuPA was not cleaved by suPAR to tcuPA, and tcuPA activity was stimulated by suPAR. These observations exclude the involvement of contaminants with protease activity that could induce scuPA cleavage to tcuPA.
3) The abolition of the suPAR-induced activation by neutralizing anti-uPAR antibodies or by ATF.
Three approaches were used to verify previously unknown interactions between suPAR/suPAR molecules and between scuPA and suPAR. The three approaches used show that su-PAR is in equilibrium between different forms (oligomers/ dimers/monomers). It is clear that the addition of equimolar concentrations of scuPA leads to the dissociation of all forms of suPAR dimerization/oligomerizaion. The observation that the monomeric scuPA-suPAR complex elutes with a longer RT as compared with any form of suPAR monomer alone (RT ϭ 8.4 versus 8.1 min) indicates that there is no detectable suPAR monomer. This conclusion is supported by the observation that scuPA runs at an RT of 10.9 min.
Dynamic light scattering measures the translational diffusion coefficient of the protein by monitoring the decay of an autocorrelation function with time. The hydrodynamic radius (R h ) of the protein can then be calculated using the StokesEinstein equation. The molecular mass of the protein is estimated by fitting the measured R h to a standard curve derived from 25 globular proteins. Proteins with major axial components, or that are spheroidal or partially unfolded, will show an apparent molecular mass that are higher than their sequence molecular mass. This is the case for scuPA, where dynamic light scattering gives a molecular mass of 73 kDa, which is much higher than the molecular mass (46.5 kDa) determined from the sequence. This excludes the possibility for a scuPA dimer and indicates that scuPA might have an elongated shape.
This conclusion is consistent with the data published by Mangle et al. (44) using small angle neutron scattering. It is also consistent with the modular structure of scuPA, which consists of an EGF domain, a kringle domain, and a serine protease domain. Futhermore, this conclusion is supported by the data obtained using SEC or EM techniques.
At high concentrations, suPAR exists mostly (98%) as a species with a molecular mass of 97.7 kDa, consistent with the formation of dimers. It is difficult to exclude the possibility of the formation of suPAR trimers, but it can be concluded that under the experimental conditions, suPAR does not exist as a monomer. The ability of suPAR to form dimers was confirmed using SEC and EM.
In contrast to the dimerization of suPAR alone, the scuPAsuPAR complex at equimolar concentrations is clearly a single species (Fig. 7C) with an R h of 4.1 nm and an apparent molecular mass of 91 kDa. It is interesting to note that the scuPAsuPAR complex has a size (4.1 nm) similar to that of the suPAR dimer (4.2 nm). This finding is in agreement with the SEC data, which shows that both suPAR and the scuPA-suPAR complex elute with similar retention times in a size exclusion column. The combined data of SEC and dynamic light scattering suggest a more compact and smaller hydrodynamic radius in the scuPA-suPAR complex.
Biophysical techniques (light scattering and SEC) and electron microscopy are complementary, as demonstrated, for example, by recent studies of the formation of oligomers and conformational changes of the integrin ␣ IIb ␤ 3 (45) . The former methods give quantitative results under aqueous conditions but can be somewhat difficult to interpret. On the other hand, electron microscopy provides a physical picture that may be used to interpret the biophysical measurements, although any quantification of the images must be done very cautiously because of artifacts arising from the conditions and methods of preparation.
The isolation of suPAR dimers and oligomers by SEC and EM indicates that the suPAR/suPAR interaction is a stable one. On the other hand, the clean and complete disruption of the suPAR dimer and oligomer by scuPA shown here suggests that the interaction of self-association of suPAR is relatively weak, compared with the interaction between suPAR and scuPA, which has a dissociation constant in the nanomolar range.
The SEC shows that suPAR in oligomers binds scuPA with lower affinity as compared with when it is present in dimers. The optical biosensor experiments are consistent with this observation, demonstrating a lower apparent affinity of suPAR to scuPA when suPAR is in solution at relatively high concentrations and not only monomers, but also higher order oligomers, are present. In addition, the deviation from linearity of Scatchard plots for the condition when suPAR is free in solution contrasted to when scuPA is free in solution is expected from this interaction model. SEC, dynamic light scattering, and electron microscopy techniques indicate for the first time that suPAR can spontaneously form dimers and oligomers. The three techniques provide evidence that the addition of scuPA leads to the dissociation of these dimers and oligomers. Thus, the binding of scuPA to suPAR leads to changes in the properties of suPAR by interfering with the dimer/oligomers structure. This may lead to the exposure of binding epitopes in suPAR that will permit its interactions with other ligands, including vitronectin (7-9) or thrombospondin (8) . By permitting novel interactions of uPAR, such a process may be involved in signal transduction.
Based on the data presented, we postulate that suPAR is present in equilibrium between monomeric, dimeric, and oligomeric forms. The binding of uPA to suPAR at equimolar concentrations induces the dissociation of the suPAR dimers. We may therefore find high moleculat weight entities when suPAR is in excess, although we have not been able to demonstrate the existence of such entities to date; this may be because of the fragile nature of such heterogenic complexes. The fragility of a suPAR/suPAR/scuPA complex may stem from the fact that although suPAR can establish interactions with scuPA or with another molecule of suPAR, it prefers the interaction with scuPA. Thus, when scuPA is present in equimolar concentration, all of the scuPA is bound to suPAR, whereas if suPAR is in excess, the free molecules of suPAR can still interact with suPAR that is bound to scuPA. The observation that in the presence of a molar excess of suPAR, the activity of uPA is greater than its activity at equimolar concentration, along with the capacity of suPAR to form dimers and oligomers, strongly supports the possibility that such an entity does exist. More efforts will be invested to demonstrate the existence of these entities.
Furthermore, the exact mechanism by which these complexes are assembled and disassembled and whether these complexes have any biological relevance need to be elucidated in the future. Indeed, the mechanism by which uPAR binds uPA is not fully understood. Our data (32) and those of others (33) indicate that uPAR contains several binding epitopes that participate in the binding of uPA. These binding epitopes are distributed on the three homologous domains that form the uPA receptor. The existence of these different epitopes on uPAR may help to provide an explanation for the formation of these novel complexes.
